119 related articles for article (PubMed ID: 14979722)
1. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy.
Sauna ZE; Andrus MB; Turner TM; Ambudkar SV
Biochemistry; 2004 Mar; 43(8):2262-71. PubMed ID: 14979722
[TBL] [Abstract][Full Text] [Related]
2. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
[TBL] [Abstract][Full Text] [Related]
3. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol.
Dey S; Hafkemeyer P; Pastan I; Gottesman MM
Biochemistry; 1999 May; 38(20):6630-9. PubMed ID: 10350482
[TBL] [Abstract][Full Text] [Related]
4. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1).
Maki N; Dey S
Biochem Pharmacol; 2006 Jul; 72(2):145-55. PubMed ID: 16729976
[TBL] [Abstract][Full Text] [Related]
6. N-ethylmaleimide increases P-glycoprotein photoaffinity labeling with iodoaryl-azidoprazosin in multidrug resistant cells.
Wang Y; Georges E
Anticancer Res; 1997; 17(1A):357-64. PubMed ID: 9066677
[TBL] [Abstract][Full Text] [Related]
7. Drug binding and nucleotide hydrolyzability are essential requirements in the vanadate-induced inhibition of the human P-glycoprotein ATPase.
Rao US
Biochemistry; 1998 Oct; 37(42):14981-8. PubMed ID: 9778376
[TBL] [Abstract][Full Text] [Related]
8. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
9. Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates.
Ghosh P; Moitra K; Maki N; Dey S
Arch Biochem Biophys; 2006 Jun; 450(1):100-12. PubMed ID: 16624245
[TBL] [Abstract][Full Text] [Related]
10. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.
Dey S; Ramachandra M; Pastan I; Gottesman MM; Ambudkar SV
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10594-9. PubMed ID: 9380680
[TBL] [Abstract][Full Text] [Related]
11. Bivalent probes of the human multidrug transporter P-glycoprotein.
Pires MM; Hrycyna CA; Chmielewski J
Biochemistry; 2006 Sep; 45(38):11695-702. PubMed ID: 16981729
[TBL] [Abstract][Full Text] [Related]
12. Analysis of random recombination between human MDR1 and mouse mdr1a cDNA in a pHaMDR-dihydrofolate reductase bicistronic expression system.
Shoshani T; Zhang S; Dey S; Pastan I; Gottesman MM
Mol Pharmacol; 1998 Oct; 54(4):623-30. PubMed ID: 9765504
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of P-glycoprotein ATPase by analogues of tetramethylrosamine: coupling of drug binding at the "R" site to the ATP hydrolysis transition state.
Tombline G; Donnelly DJ; Holt JJ; You Y; Ye M; Gannon MK; Nygren CL; Detty MR
Biochemistry; 2006 Jul; 45(26):8034-47. PubMed ID: 16800628
[TBL] [Abstract][Full Text] [Related]
14. Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
Chan KF; Zhao Y; Burkett BA; Wong IL; Chow LM; Chan TH
J Med Chem; 2006 Nov; 49(23):6742-59. PubMed ID: 17154505
[TBL] [Abstract][Full Text] [Related]
15. Both ATP sites of human P-glycoprotein are essential but not symmetric.
Hrycyna CA; Ramachandra M; Germann UA; Cheng PW; Pastan I; Gottesman MM
Biochemistry; 1999 Oct; 38(42):13887-99. PubMed ID: 10529234
[TBL] [Abstract][Full Text] [Related]
16. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder.
Chearwae W; Anuchapreeda S; Nandigama K; Ambudkar SV; Limtrakul P
Biochem Pharmacol; 2004 Nov; 68(10):2043-52. PubMed ID: 15476675
[TBL] [Abstract][Full Text] [Related]
17. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
Rautio J; Humphreys JE; Webster LO; Balakrishnan A; Keogh JP; Kunta JR; Serabjit-Singh CJ; Polli JW
Drug Metab Dispos; 2006 May; 34(5):786-92. PubMed ID: 16455806
[TBL] [Abstract][Full Text] [Related]
18. Polyene multi-drug resistance reversal agents.
Andrus MB
Curr Opin Drug Discov Devel; 2004 Nov; 7(6):823-31. PubMed ID: 15595443
[TBL] [Abstract][Full Text] [Related]
19. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle.
Qu Q; Russell PL; Sharom FJ
Biochemistry; 2003 Feb; 42(4):1170-7. PubMed ID: 12549939
[TBL] [Abstract][Full Text] [Related]
20. Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP.
Sauna ZE; Kim IW; Nandigama K; Kopp S; Chiba P; Ambudkar SV
Biochemistry; 2007 Dec; 46(48):13787-99. PubMed ID: 17988154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
